X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
http://portal.anvisa.gov.br/noticias/-/asset_publisher/FXrpx9qY7FbU/content/hepatite-c-anvisa-alerta-sobre-medicamento-falsificado/219201?p_p_auth=Yai2lXHR&inheritRedirect=false&redirect=http%3A%2F%2Fportal.anvisa.gov.br%2Fnoticias%3Fp_p_auth%3DYai2lXHR%26p_p_id%3D101_INSTANCE_FXrpx9qY7FbU%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3D_118_INSTANCE_KzfwbqagUNdE__column-2%26p_p_col_count%3D2
https://www.in-pharmatechnologist.com/Article/2019/09/30/AbbVie-receives-approval-HCV-treatment
https://www.biopharmadive.com/news/regulatory-barriers-limit-alternative-state-drug-payment-models/563204/
http://www.pmlive.com/pharma_news/nhs_england_sees_off_abbvies_hep_c_legal_challenge_1275737
https://www.fiercepharma.com/pharma/scotus-declines-to-hear-appeals-from-merck-gilead-two-high-profile-drug-battles
https://www.fiercepharma.com/marketing/abbvie-highlights-mavyret-s-8-week-advantage-new-ad-campaign-as-it-continues-its-hep-c
https://endpts.com/what-do-martin-shkreli-gilead-and-takeda-have-in-common-they-all-figure-prominently-in-the-new-top-20-list-of-the-worlds-most-expensive-drugs/
https://www.biopharmadive.com/news/express-scripts-flex-formulary-gilead-authorized-alternatives/542259/
https://www.fiercepharma.com/pharma/investigators-looking-at-pharma-s-nurse-educator-programs-filings
https://www.fiercepharma.com/pharma/merck-asks-supreme-court-to-take-up-gilead-patent-fight-after-lower-court-nixed-200m-verdict
https://www.bloomberg.com/news/articles/2018-09-24/gilead-to-sell-cheaper-versions-of-drug-that-sparked-cost-debate
https://www.reuters.com/article/us-gilead-sciences-genericdrugs/gilead-to-launch-generic-versions-of-its-hepatitis-drugs-idUSKCN1M42H6
https://www.fiercepharma.com/pharma/gilead-s-top-execs-milligan-and-martin-stepping-down
https://www.thehindubusinessline.com/companies/two-pre-grant-patent-oppositions-filed-on-gileads-hepatitis-c-medicines/article24377414.ece
https://www.fiercebiotech.com/biotech/enyo-raises-47m-to-bring-hep-b-nash-drug-to-phase-2?mkt_tok=eyJpIjoiTjJJeU5XTmhOVGMyWW1JeCIsInQiOiJXNU9EMUpqRW1qNFA4QnNKZEFrNm0yWjVXVnhBQzBjMWFpZTNEcVZmcmsyZGZQUlA1Sjdwc0RXeWtmTXNJdHlxR3Yzajc4ZGZwUGdlbWZ4WllrQWM0MVRBeTdUUjhtZ3B4dXdrWWRMcmgwb05RMEpONjM1OHJOakpXU1N4UVhBTCJ9&mrkid=67302085
https://www.fiercepharma.com/pharma/celgene-abbvie-extract-better-pricing-q4-as-some-large-pharmas-struggle-report
https://www.reuters.com/article/us-gilead-sciences-lawsuit/gilead-wins-reversal-of-2-54-billion-hepatitis-c-drug-patent-verdict-idUSKCN1G10MH
https://www.fiercepharma.com/pharma/retail-drug-spending-grew-just-1-3-last-year-cms-analysis-concludes
http://www.nasdaq.com/article/heres-whats-has-happened-in-the-hcv-space-lately-cm856488
http://www.fiercepharma.com/vaccines/university-maryland-team-secures-6m-nih-fund-for-novel-hcv-vaccine
http://theubpost.mn/2017/04/21/pm-meets-with-gilead-sciences-representatives-to-fight-hepatitis/
https://globenewswire.com/news-release/2017/04/11/958691/0/en/Tonix-Pharmaceuticals-Reports-Results-from-U-S-FDA-Initial-Cross-Disciplinary-Breakthrough-Meeting-on-TNX-102-SL-for-Posttraumatic-Stress-Disorder.html
http://www.nasdaq.com/article/gilead-gild-hcv-drugs-gets-fda-nod-for-label-expansion-cm772427
http://www.fiercepharma.com/regulatory/gilead-notches-sovaldi-harvoni-approvals-pediatric-patients
http://www.pharmamanufacturing.com/industrynews/2017/fda-approves-first-hep-c-drugs-for-kids/
http://www.fiercepharma.com/marketing/tip-off-for-dtc-fiercemadness-contest-voting-opens-for-play-ads
http://www.fiercepharma.com/marketing/baby-boomers-targeted-gilead-hepatitis-c-awareness-campaign-even-as-drug-s-fortunes-drop
http://www.biospace.com/News/how-gilead-just-lost-9-billion-in-market-value/446267/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.fiercepharma.com/pharma/value-investors-pile-into-gilead-expecting-strong-long-term-growth-report
http://www.fiercepharma.com/pharma/new-hep-c-meds-carry-risk-for-liver-failure-death-report
http://www.pmlive.com/pharma_news/two_new_hepatitis_c_therapies_fast-tracked_in_europe_1184949
http://www.biospace.com/News/why-the-government-should-pay-156-billion-to-own/444304/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biologics-enter-top-selling-drugs-list/articleshow/56214879.cms
https://www.statnews.com/pharmalot/2016/12/15/gilead-merck-hepatitis-c-patents/
http://www.fiercepharma.com/pharma/gilead-and-express-scripts-make-peace-hep-c-2017-formulary-deal
http://www.fiercepharma.com/pharma/j-j-s-xarelto-abbvie-s-humira-shelled-out-most-doc-payments-last-year
http://www.fiercepharma.com/pharma/biosim-threats-coming-fast-for-world-s-top-2017-drugs
http://www.fiercepharma.com/marketing/gilead-comes-around-truvada-prep-marketing-opening-up-a-new-world-hiv-sales
http://www.biospace.com/News/gileads-rd-woes-could-make-it-an-attractive-target/439689/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.fiercepharma.com/pharma/medicare-medcaid-pony-up-for-big-price-hikes-2015-data-show
http://www.fiercepharma.com/pharma/already-a-hated-pricing-foe-germany-eyes-stiffer-limits-new-controls
http://www.drug-dev.com/Main/Back-Issues/HCV-MARKET-Recent-Success-in-HCV-Treatment-Brings-1213.aspx
http://www.biospace.com/News/gilead-drops-another-bombshell-will-shift-rd-cash/437873/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.marketwatch.com/story/gilead-sales-of-hepatitis-c-drugs-slump-2016-11-01?
http://www.fiercepharma.com/pharma/surprise-gilead-s-hep-c-wonder-harvoni-costs-less-u-s-than-eu-japan
http://www.fiercepharma.com/pharma/pfizer-amgen-most-likely-to-bid-for-medivation-analysts
http://www.pharmamanufacturing.com/industrynews/2016/u-s-judge-frees-gilead-from-200m-in-damages-to-merck/
http://www.bloomberg.com/news/articles/2016-04-30/gilead-judge-re-opens-case-amid-claim-merck-scientist-lied
http://www.fiercepharma.com/pharma/gilead-faces-hep-c-slowdown-q1-miss-sales-revenue
Market Place
Share 
